Navigation Links
NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare
Date:9/29/2010

ALEXANDRIA, Va., Sept. 29 /PRNewswire-USNewswire/ -- The National Community Pharmacists Association (NCPA) expressed strong support for an investigation into CVS Caremark launched by the U.S. Senate Special Committee on Aging reported earlier today on the blog Pharmalot.

(Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO)

In response, NCPA President Joseph H. Harmison, PD and Arlington, Texas pharmacy owner, issued the following statement:

"Complaints continue to increase from patients and community pharmacists alleging CVS Caremark of engaging in anti-consumer, anti-competitive behavior. We commend Chairman Herb Kohl (D-Wisc.) for doing the right thing on behalf of patients and pharmacists in Wisconsin and across the nation.  Seniors are both the most in need of pharmacy services and the patients arguably most vulnerable to the misleading and deceptive tactics of which CVS Caremark is accused.

"CVS Caremark's strong-armed efforts to gain market share appear to be compromising patient care while inflating costs for seniors, the Medicare program and taxpayers. For example, retirees Max and Jan Hauser discovered that, under their Medicare drug plan administered by CVS Caremark, the cholesterol drug Simvastatin that cost them nothing at a local independent pharmacy cost them $165.99 at CVS for a three-month supply. As reported by WCNC-TV they were also charged more by CVS for ulcer drugs and blood pressure medicine. The combined higher costs charged by CVS pushed the fixed-income couple into their plan's coverage gap (or 'donut hole') sooner, significantly increasing their out-of-pocket drug costs.

"In addition, seniors who prefer the face to face service and counseling of their independent community pharmacist are forced by CVS Caremark to switch to its mail order or to travel greater distances to the nearest CVS location. In the newly released J.D. Power and Associates 2010 National Pharmacy Study, patients rated CVS Caremark retail and mail order pharmacies significantly lower than its rivals in customer satisfaction.

"The Senate committee joins a long and growing list of investigations into anti-consumer, anti-competitive allegations against CVS Caremark. The Federal Trade Commission is in the midst of a non-public investigation involving both its Bureaus of Competition and Consumer Protection and with the support of dozens of members of Congress. In addition, approximately 24 states are pursuing their own investigations. Community pharmacists and their patients are looking for comprehensive relief from the FTC and other regulators to stop any anti-competitive and deceptive practices by CVS Caremark."

The National Community Pharmacists Association (NCPA®) represents America's community pharmacists, including the owners of more than 22,700 independent community pharmacies, pharmacy franchises, and chains. Together they represent an $88 billion health-care marketplace, employ over 65,000 pharmacists, and dispense over 40% of all retail prescriptions. To learn more go to www.ncpanet.org or read NCPA's blog, The Dose, at http://ncpanet.wordpress.com.


'/>"/>
SOURCE National Community Pharmacists Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Test for Life Commends North Carolina Rules Commission for Implementing CDC Recommendations for HIV Testing
2. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
3. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
4. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
5. Lung Cancer Alliance Commends NCCN on Screening Guidelines
6. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
7. Task Force Recommends Screening for Hearing Loss in All Newborns
8. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
9. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
10. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
11. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
Breaking Medicine Technology:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... preserve fertility and create life. Although frozen embryos have a slight statistical advantage ... , “Egg freezing is a wonderful opportunity for women undergoing medical treatment or ...
(Date:9/21/2017)... Aliso Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... never been so fun and easy to do. Users can select from up to ... more all with a click of a mouse all within Final Cut Pro ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... Sept. 26, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... easy to get things wrong, run afoul of The Quality System Regulation (§820.250), ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Infinity Behavioral Health Services for professionals in the addiction treatment industry entitled: ... . , Insurance companies and state and federal governments are increasingly scrutinizing ...
(Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
Breaking Medicine News(10 mins):